Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe parkinsonian's patients

被引:0
|
作者
Vaamonde, J [1 ]
Ibàñez, R [1 ]
Gudin, M [1 ]
Hernández, A [1 ]
机构
[1] Complejo Hosp Ciudad Real, Serv Neurol, Ciudad Real 13002, Spain
来源
NEUROLOGIA | 2003年 / 18卷 / 03期
关键词
Parkinson's disease; severity; motor complications;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Daily fluctuations of motor performance and dyskinesias in patients with Parkinson's disease (PD) treated with levodopa represent a difficult challenge to our understanding. We report 10 patients diagnosed of severe PD (Hoehn and Yahr: III-IV/V) treated with levodopa (range of dose: 750-900 mg/day) in single drug therapy since their diagnosis (mean time of levodopatherapy: 4.8 +/- 2.4 months, range: 3-6 months). All patients developed motor complications within weeks to months after initiating L-dopatherapy. Two patients received an intravenous apomorphine infusion (mean dose: 8.5 mg/day) during a mean time of 7.5 hours, but motor complications persisted during the infusion in spite of continuous dopaminergic stimulus. The degree of nigrostriatal damage (disease severity) seems to be a very important risk factor for the development of treatment-related motor complications.
引用
收藏
页码:162 / 165
页数:4
相关论文
共 50 条
  • [1] Clinical pharmacology of L-dopa-induced dyskinesias in Parkinsonian patients
    Rascol, O
    Brefel-Courbon, C
    Blin, O
    THERAPIE, 1998, 53 (01): : 43 - 48
  • [2] Calcium Homeostasis Is Dysregulated in Parkinsonian Patients With L-DOPA-Induced Dyskinesias
    Blandini, Fabio
    Bazzini, Eleonora
    Marino, Franca
    Saporiti, Federica
    Armentero, Marie-Therese
    Pacchetti, Claudio
    Zangaglia, Roberta
    Martignoni, Emilia
    Lecchini, Sergio
    Nappi, Giuseppe
    Cosentino, Marco
    CLINICAL NEUROPHARMACOLOGY, 2009, 32 (03) : 133 - 139
  • [3] Comparison of motor fluctuations and L-dopa-induced dyskinesias in patients with familial and sporadic Parkinson's disease
    Papapetropoulos, S
    Argyriou, AA
    Ellul, J
    Chroni, E
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (02) : 115 - 119
  • [4] L-Dopa-Induced Dyskinesias are Reduced by Propranolol in Parkinsonian Mice
    Bamford, Nigel
    Shi, Ziqing
    Bamford, Ian
    Mckinley, Jonathan
    NEUROLOGY, 2019, 92 (15)
  • [5] Propranolol Relieves L-Dopa-Induced Dyskinesias in Parkinsonian Mice
    Shi, Z.
    McKinley, J.
    Bamford, I
    Bamford, N.
    ANNALS OF NEUROLOGY, 2018, 84 : S367 - S367
  • [6] nAChR agonists reduce L-dopa-induced dyskinesias in parkinsonian rats
    Quik, M.
    Huang, L. Z.
    Lee, Y.
    Carroll, I. F.
    Parameswaran, N.
    BIOCHEMICAL PHARMACOLOGY, 2009, 78 (07) : 922 - 922
  • [7] Role of striatal ΔFosB in L-Dopa-induced dyskinesias of parkinsonian nonhuman primates
    Beck, Goichi
    Singh, Arun
    Zhang, Jie
    Potts, Lisa F.
    Woo, Jong-Min
    Park, Eun S.
    Mochizuki, Hideki
    Mouradian, M. Maral
    Papa, Stella M.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (37) : 18664 - 18672
  • [8] Mirtazapine in L-dopa-induced dyskinesias
    Meco, G
    Fabrizio, E
    Di Rezze, S
    Alessandri, A
    Pratesi, L
    CLINICAL NEUROPHARMACOLOGY, 2003, 26 (04) : 179 - 181
  • [9] Pathophysiology of L-dopa-induced dyskinesias
    Bédard, PJ
    Blanchet, PJ
    Lévesque, D
    Soghomonian, JJ
    Grondin, R
    Morissette, M
    Goulet, M
    Calon, F
    Falardeau, P
    Gomez-Mancilla, B
    Doucet, JP
    Robertson, GS
    DiPaolo, T
    MOVEMENT DISORDERS, 1999, 14 : 4 - 8
  • [10] Role for α6 nicotinic receptors in L-dopa-induced dyskinesias in parkinsonian mice
    Quik, Maryka
    Park, Keon Min
    Hrachova, Maya
    Mallela, Archana
    Huang, Luping Z.
    McIntosh, J. Michael
    Grady, Sharon R.
    NEUROPHARMACOLOGY, 2012, 63 (03) : 450 - 459